PRESS RELEASES

Date Title and Summary Additional Formats
Toggle Summary August Watanabe, M.D. joins board of directors at Endocyte View HTML
Toggle Summary Cancer research firm among companies to benefit from grants View HTML
Toggle Summary Chandra Lovejoy joins Endocyte as Director of Regulatory Affairs View HTML
Toggle Summary Clinical Study Shows Involvement of Activated Macrophages in Osteoarthritis, Identified by Endocyte's Etarfolatide
Etarfolatide Differentiates Inflammatory from Non-Inflammatory Disease States in Osteoarthritis Patients Data Presented at the OARSI 2013 World Congress on Osteoarthritis PHILADELPHIA , April 25, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted
View HTML
Toggle Summary Colin Goddard, Ph.D., Joins the Endocyte Board of Directors
WEST LAFAYETTE, Ind. , Nov. 7, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that
View HTML
Toggle Summary Data on Endocyte's Vintafolide and Etarfolatide to be Presented at the 3rd European Lung Cancer Conference
WEST LAFAYETTE, Ind. , April 20, 2012 (GLOBE NEWSWIRE) -- Endocyte, Inc . (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that previously reported data on vintafolide
View HTML
Toggle Summary Data Published Identify the Folate Receptor as a Potential Biomarker for Targeted Therapies in a Majority of Lung Cancers
- Results Show 72 Percent of Adenocarcinomas and 51 Percent of Squamous Cell Carcinoma of the Lung Express Folate Receptor - - Data Published in Archives of Pathology & Laboratory Medicine - WEST LAFAYETTE, Ind. , Oct. 12, 2012 (GLOBE NEWSWIRE) --  Endocyte, Inc.
View HTML
Toggle Summary Design and Synthesis Strategies of Endocyte's Small Molecule Drug Conjugate (SMDC) Technology to be Presented at the 242nd American Chemical Society (ACS) National Meeting & Exposition
WEST LAFAYETTE, Ind. , Aug. 23, 2011 (GLOBE NEWSWIRE) -- Endocyte, Inc . (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy, today announced that the company's proprietary design strategies
View HTML
Toggle Summary Dr. Lesley Russell Joins the Endocyte Board of Directors
WEST LAFAYETTE, Ind. , Jan. 8, 2013 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT), a biopharmaceutical company developing targeted small molecule drug conjugates (SMDCs) and companion imaging diagnostics for personalized therapy in cancer and other serious diseases, today announced Lesley
View HTML
Toggle Summary Emory Researchers Awarded $1.6 Million to Study Common Type of Pituitary Tumor View HTML